Literature DB >> 34029506

Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations.

Anita Kumari1, Lovika Mittal1, Mitul Srivastava1, Shailendra Asthana1.   

Abstract

The main protease, Mpro/3CLpro, plays an essential role in processing polyproteins translated from viral RNA to produce functional viral proteins and therefore serve as an attractive target for discovering COVID-19 therapeutics. The availability of both monomer and dimer crystal bound with a common ligand, '13b' (α-ketoamide inhibitor), opened up opportunities to understand the Mpro mechanism of action. A comparative analysis of both forms of Mpro was carried out to elucidate the binding site architectural differences in the presence and absence of '13b'. Molecular dynamics simulations suggest that the presence of '13b' enhances the stability of Mpro than the unbound APO form. The N- and C- terminals of both the protomers stabilize each other, and making it's interface essential for the active form of Mpro. In comparison to monomer, the relatively high affinity of '13b' is gained in dimer pocket due to the high stability of the pocket by the interaction of S1 residue of chain B with residues F140, E166 and H172 of chain A, which is absent in monomer. The comprehensive essential dynamics, protein structure network analysis and thermodynamic profiling highlight the hot-spots, pivotal in molecular recognition process at protein-ligand and protein-protein interaction levels, cross-validated through computational alanine scanning study. A comparative description of '13b' binding mechanism in both forms illustrates valuable insights into the inhibition mechanism and the selection of critical residues suitable for the structure-based approaches for the identification of more potent Mpro inhibitors.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  MM-GBSA/MM-PBSA; Molecular dynamics simulations; active form of Mpro; binding mode analysis; computational alanine scanning; principal component analysis; protein structure network analysis

Year:  2021        PMID: 34029506     DOI: 10.1080/07391102.2021.1927844

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  3 in total

1.  Drug repurposing and computational modeling for discovery of inhibitors of the main protease (Mpro) of SARS-CoV-2.

Authors:  José Rogério A Silva; Hendrik G Kruger; Fábio A Molfetta
Journal:  RSC Adv       Date:  2021-07-02       Impact factor: 4.036

2.  Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease.

Authors:  Anna Pavlova; Diane L Lynch; Isabella Daidone; Laura Zanetti-Polzi; Micholas Dean Smith; Chris Chipot; Daniel W Kneller; Andrey Kovalevsky; Leighton Coates; Andrei A Golosov; Callum J Dickson; Camilo Velez-Vega; José S Duca; Josh V Vermaas; Yui Tik Pang; Atanu Acharya; Jerry M Parks; Jeremy C Smith; James C Gumbart
Journal:  Chem Sci       Date:  2020-11-26       Impact factor: 9.825

3.  Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (Mpro) elucidated by microsecond MD simulations.

Authors:  Yasser Hayek-Orduz; Andrés Felipe Vásquez; María Francisca Villegas-Torres; Paola A Caicedo; Luke E K Achenie; Andrés Fernando González Barrios
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.